HIF gene mutation found in tumor cells offers new clues about cancer metabolism

ScienceDaily (Sep. 5, 2012) ? For the first time, a mutation in HIF2?, a specific group of genes known as transcription factors that is involved in red blood cell production and cell metabolism, has been identified in cancer tumor cells.

Researchers from Huntsman Cancer Institute (HCI) at the University of Utah and the National Institutes of Health found the mutation in tumor cells of two patients with the rare cancers paraganglioma/pheochromocytoma and somatostatinoma. The mutation was previously identified in connection with a non-cancerous hereditary condition, but never before in spontaneously arising cancers. The research results appear in the September 6, 2012 issue of the New England Journal of Medicine.

Transcription factors are proteins that bind to specific sequences of DNA to regulate cell functions. Hypoxia-inducible factors (HIFs) are transcription factors that control a wide range of functions connected to the way cells respond to oxygen, including metabolism (the way energy is produced) and the creation of red blood cells. Increased amounts of HIF in cancer cells was found to be responsible for the unique way they generate energy, referred to as the Warburg effect, named for Otto Warburg, a German physiologist who received the 1931 Nobel Prize in Physiology for this research.

"These HIF pathway mutations were first discovered while studying people with a condition called polycythemia that makes the body overproduce red blood cells," said one of the senior authors, Josef Prchal, M.D., professor in the Division of Hematology and Hematologic Malignancies at the University of Utah School of Medicine, an HCI investigator, and an expert on polycythemic disorders who has previously discovered other mutations in other HIF pathway genes.

The findings raise some important questions for future research. "The patients in which we found these mutations have a rare combination of diseases, paraganglioma/pheochromocytoma and polycythemia, yet they shared similar mutations," said Prchal. "Learning whether HIF pathway mutations are present in other cancers could increase understanding of the mechanisms of cancer cell metabolism and offer a possible new target for cancer treatment development."

Felipe Lorenzo, M.D., Ph.D., postdoctoral fellow in the University of Utah Division of Hematology and Hematologic Malignancies, collaborated on this article. Other co-authors are associated with various entities of the National Institutes of Health. The research was supported, in part, by the Intramural Research Program of the National Institutes of Health, the National Institute of Child Health and Human Development, and the National Institute of Neurological Disorders and Stroke and VAH Merit Award to Dr. Prchal. The National Institutes of Health support Huntsman Cancer Institute through P30 CA042014.

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:

---

Story Source:

The above story is reprinted from materials provided by University of Utah Health Sciences, via Newswise.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.

---

Journal Reference:

1. Zhengping Zhuang, Chunzhang Yang, Felipe Lorenzo, Maria Merino, Tito Fojo, Electron Kebebew, Vera Popovic, Constantine A. Stratakis, Josef T. Prchal, Karel Pacak. Somatic HIF2A Gain-of-Function Mutations in Paraganglioma with Polycythemia. New England Journal of Medicine, 2012; 367 (10): 922 DOI: 10.1056/NEJMoa1205119

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/~3/3_OaazbbBAs/120905183003.htm

lana del rey snl enemy of the state golden globe nominees joe philbin miss america pageant 2012 shipwreck jose aldo vs chad mendes